Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent agonist of the GLP-2 receptor (GLP-2R), effectively reducing fecal output and enhancing intestinal absorption, while also alleviating inflammation in the small intestine. It holds potential for use in researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].